A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers

NCT06577298 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

480

Enrollment

INDUSTRY

Sponsor class

Conditions

Poliomyelitis

Interventions

BIOLOGICAL: Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose
BIOLOGICAL: VLP-Polio medium dose
BIOLOGICAL: VLP-Polio high dose
BIOLOGICAL: Vaccine Poliomyelitis Inactivated (IPV)

Sponsor

CanSino Biologics Inc.